PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23058106-1 2012 Two closely related binding modes have previously been proposed for the ATP-competitive benzimidazole class of checkpoint kinase 2 (CHK2) inhibitors; however, neither binding mode is entirely consistent with the reported SAR. benzimidazole 88-101 sarcosine dehydrogenase Homo sapiens 221-224 23360431-5 2013 A predictive model was developed from the initial SAR in which the potency of the analogues correlated with the ability of the substituent in the 7-position of the azaindole to adopt a coplanar conformation by either forming internal hydrogen bonds or avoiding repulsive substitution patterns. benzimidazole 164-173 sarcosine dehydrogenase Homo sapiens 50-53 23058106-2 2012 Unconstrained rigid docking of benzimidazole ligands into representative CHK2 protein crystal structures reveals an alternative binding mode involving a water-mediated interaction with the hinge region; docking which incorporates protein side chain flexibility for selected residues in the ATP binding site resulted in a refinement of the water-mediated hinge binding mode that is consistent with observed SAR. benzimidazole 31-44 sarcosine dehydrogenase Homo sapiens 406-409 20545947-1 2010 From an azaindole lead, identified in high throughput screen, a series of potent bis-azaindole inhibitors of IGF1-R have been synthesized using rational drug design and SAR based on a in silico binding mode hypothesis. benzimidazole 8-17 sarcosine dehydrogenase Homo sapiens 169-172 22765895-4 2012 Through targeted SAR and structure-guided design, new imidazopyridine and imidazopyridazine scaffolds were identified that demonstrated superior inhibition of mTOR in cellular assays, selectivity over the closely related PIKK family and improved in vivo clearance over our previously reported benzimidazole series. benzimidazole 293-306 sarcosine dehydrogenase Homo sapiens 17-20 21185722-2 2011 The SAR leading to the identification of the optimal azaindole regioisomer as well as the pharmacokinetics and off-target activities of the most potent antagonists are disclosed. benzimidazole 53-62 sarcosine dehydrogenase Homo sapiens 4-7 20153189-0 2010 SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors. benzimidazole 30-43 sarcosine dehydrogenase Homo sapiens 0-3 20185309-0 2010 Benzimidazole Thumb Pocket I finger-loop inhibitors of HCV NS5B polymerase: improved drug-like properties through C-2 SAR in three sub-series. benzimidazole 0-13 sarcosine dehydrogenase Homo sapiens 118-121 20185309-1 2010 SAR at the C-2 position of benzimidazole-based Thumb Pocket I inhibitors of HCV NS5B polymerase revealed parallel activity for distinct sub-series that harbor 5-hydroxytryptophan amides, neutral thiazole isosteres or recently disclosed cinnamic acid diamides. benzimidazole 27-40 sarcosine dehydrogenase Homo sapiens 0-3 19716296-1 2009 SAR for a wide variety of heterocyclic replacements for a benzimidazole led to the discovery of functionalized 2-pyridyl amides as novel inhibitors of the hedgehog pathway. benzimidazole 58-71 sarcosine dehydrogenase Homo sapiens 0-3 19769332-4 2009 Systematic replacement of each of the unfused carbon atoms in the phenyl ring of the indole moiety by a nitrogen atom provided four different azaindole derivatives that displayed a clear SAR for antiviral activity and all of which displayed marked improvements in pharmaceutical properties. benzimidazole 142-151 sarcosine dehydrogenase Homo sapiens 187-190 8401764-4 1993 The preliminary SAR studies indicate the importance of chlorine atom at position 3 in diazine nucleus and of alkyl substituents in benzimidazole moiety for positive inotropic effects. benzimidazole 131-144 sarcosine dehydrogenase Homo sapiens 16-19 18242988-2 2008 Systematic modification of the benzimidazole core and tethered acetophenone moiety established tractable SAR of analogs with improved physicochemical properties and sub-micromolar activity across both human and murine receptors. benzimidazole 31-44 sarcosine dehydrogenase Homo sapiens 105-108 16442290-3 2006 Here, a series of non-benzimidazole analogs intended to define the scope of the SAR about this new series of inhibitor, and allow for refinement of the binding model of these compounds to the chk2 kinase is described. benzimidazole 22-35 sarcosine dehydrogenase Homo sapiens 80-83 26526214-1 2015 In this Letter, we report the continued optimization of the N-acyl-2-aminobenzimidazole series, focusing in particular on the N-alkyl substituent and 5-position of the benzimidazole based on the binding mode and the early SAR. benzimidazole 74-87 sarcosine dehydrogenase Homo sapiens 222-225 25352112-5 2015 This review will further be helpful for the researcher on the basis of substitution pattern around the nucleus with an aim to help medicinal chemists for developing an SAR on benzimidazole drugs/compounds. benzimidazole 175-188 sarcosine dehydrogenase Homo sapiens 168-171 25599839-5 2015 The synthesis, biological evaluation and SAR of novel benzimidazole derivatives as KOR agonists are described. benzimidazole 54-67 sarcosine dehydrogenase Homo sapiens 41-44 24461289-0 2014 Benzimidazole CB2 agonists: design, synthesis and SAR. benzimidazole 0-13 sarcosine dehydrogenase Homo sapiens 50-53 24533813-9 2014 In this article benzimidazole inhibitors are reported with their mechanisms of action, structure-activity relationship (SAR) and biological properties. benzimidazole 16-29 sarcosine dehydrogenase Homo sapiens 87-124 23815580-5 2013 In the present review, benzimidazole derivatives with different pharmacological activities are described on the basis of substitution pattern around the nucleus with an aim to help medicinal chemists for the development of SAR on benzimidazoles for each activity. benzimidazole 23-36 sarcosine dehydrogenase Homo sapiens 223-226 23544603-5 2013 In the present review, benzimidazole derivatives with different pharmacological activities are described on the basis of substitution pattern around the nucleus with an aim to help medicinal chemists for the development of SAR on benzimidazoles for each activity. benzimidazole 23-36 sarcosine dehydrogenase Homo sapiens 223-226